Lupus & antiphospholipid syndrome
Development of the 2023 American College of Rheumatology (ACR) / EULAR Antiphospholipid Syndrome Classification Criteria, Phase III ‐C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions
Authors' conclusion
Referred suspected APS cases provided insight into associations of individual candidate criteria with APS likelihood. RR analyses helped refine items and organize the draft classification system into eight additive and independent clinical and laboratory domains.
Study context
- Population
- aPL-positive cases referred for "suspected antiphospholipid syndrome (APS)"
- Participants
- 314 suspected APS cases
- Comparison
- Candidate criteria in "highly likely" vs "equivocal or unlikely" APS
- Highly likely APSn = 137
- Equivocal/unlikely APSn = 177reference
- Outcome
- Association of candidate criteria with highly likely APS
Methodological detailsphase III, derivation cohort of patient scenarios, Poisson regression, Likert-scale case likelihood by treating physicians
- Phase III, derivation cohort of patient scenarios
- Poisson regression
- Likert-scale case likelihood by treating physicians
Performance
As reported in the abstract
Relative risk (95% CI)
VTERR 1.56 [95% CI 0.89-2.75] with provoking risk factors
4.31(2.11–8.78)
ATRR 1.64 [95% CI 0.77-3.51] with provoking risk factors
3.48(1.91–6.32)
- Persistent LA, aCL IgG ≥40 U and anti-β2-glycoprotein-I IgG ≥40 U positively associated with highly likely APS
- all P < 0.05
Original publication
Development of the 2023 ACR / EULAR Antiphospholipid Syndrome Classification Criteria, Phase III ‐C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions. Arthritis Care Res (Hoboken). Published 5 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →